KORU Medical Systems (KRMD) vs Pulmonx (LUNG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pulmonx (LUNG) has outperformed KORU Medical Systems (KRMD) over the past year, gaining 78.5% versus a loss of 33.3%. Over five years, KRMD leads with a -12.6% price change compared with -92.4% for LUNG. KORU Medical Systems is the larger company by market cap ($138.4 million vs $111.9 million), about 1.2 times the size.
KORU Medical Systems converts more of its revenue into profit, with a net margin of -6.4% versus -59.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRMD | LUNG |
|---|---|---|
| Share price | $3.19 | $2.57 |
| Market cap | $138.37M | $111.93M |
| 1-day change | -7.27% | -6.20% |
| YTD return | -45.09% | +16.29% |
| 1-year return | -33.26% | +78.47% |
| 5-year return | -12.60% | -92.39% |
| Forward P/E | 45.57 | — |
| EPS (TTM) | $-0.02 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.13M | $90.50M |
| Revenue growth (YoY) | +22.23% | +8.01% |
| Net income (latest FY) | $-2.64M | $-54.00M |
| Gross margin | 62.26% | 74.19% |
| Operating margin | -7.23% | -59.30% |
| Net margin | -6.41% | -59.67% |
| 52-week high | $6.61 | $3.25 |
| 52-week low | $2.86 | $1.13 |
| Distance from 52-week high | -51.73% | -20.92% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +92.16% | +65.37% |
| Average volume | 223.45K | 641.52K |
| Shares outstanding | 43.38M | 43.55M |
| Employees | 73 | 296 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUNG has outperformed KRMD by 111.7 percentage points over the past year.
- KORU Medical Systems is more profitable, keeping -6.4 cents of every revenue dollar as net income versus -59.7 cents for Pulmonx.
- KORU Medical Systems grew revenue faster in its latest fiscal year (+22.23% vs +8.01%).
About KORU Medical Systems
KRMD stock →KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally.
Health Care · Medical/Dental Instruments · 73 employees
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Health Care · Medical/Dental Instruments · 296 employees
KRMD vs LUNG FAQ
Which is bigger, KORU Medical Systems or Pulmonx?
KORU Medical Systems (KRMD) is larger, with a market capitalization of $138.37M compared with $111.93M for Pulmonx (LUNG).
Which stock has performed better over the past year, KRMD or LUNG?
LUNG returned +78.47% over the past 12 months, compared with -33.26% for KRMD (price return, excluding dividends). Past performance does not predict future results.
Are KORU Medical Systems and Pulmonx in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.